Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-09-05
2008-11-25
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007910, C435S007920, C530S387200
Reexamination Certificate
active
07455976
ABSTRACT:
A complex having oxLDL bound covalently to β2-GPI can be used as a standard for measuring a β2-GPI/oxLDL complex in the living body thereby measuring the β2-GPI/oxLDL complex in the living body more accurately and strictly, and can be utilized to provide a new measurement method, detection method, kit etc.
REFERENCES:
patent: 5900359 (1999-05-01), Matsuura et al.
patent: 7-306202 (1995-11-01), None
patent: 95/09363 (1995-04-01), None
K. Kobayashi et al., “A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages”, Journal of Lipid Research, vol. 42, pp. 697-709, 2001.
D. Steinberg et al., “Modification of Low-Density Lipoprotein that Increase its Atherogenicity”, The New England Journal of Medicine, vol. 320, No. 14, pp. 915-924, Apr. 6, 1989.
H. C. Boyd et al., “Direct Evidence for a Protein Recognized by a Monoclonal Antibody against Oxidatively Modified LDL in Atherosclerotic Lesions from a Watanabe Heritable Hyperlipidemic Rabbit”, American Journal of Pathology, vol. 135, No. 5, pp. 815-825, Nov. 1989.
Y. Nagano et al., “High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification”, Proc. Natl. Acad. Sci., vol. 88, pp. 6457-6461, Aug. 1991.
M. Chang et al., “C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids”, PNAS, vol. 99, No. 20, pp. 13043-13048, Oct. 1, 2002.
H. Kamido et al., “Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins”, Journal of Lipid Research, vol. 36, pp. 1876-1886, 1995.
G. Hoppe et al., “Oxidation products of cholesteryl linoleate are resistant to hydrolysis is macrophages, form complexes with proteins, and are present in human atherosclerotic lesions”, Journal of Lipid Research, vol. 38, pp. 1347-1360, 1997.
H. Kamido et al., “Identification of cholesterol-bound aldehydes in copper-oxidized low density liproprotein”, FEBS Letters, vol. 304, No. 2 & 3, pp. 269-272, Jun. 1992.
J. Hulthe et al., “Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the atherosclerosis and insulin resistance (AIR) study”, Clinical Science, vol. 100, pp. 371-378, 2001.
M. Ryan et al., “Antibodies to oxidized lipoproteins and their relationship to myocardial infarction”, Q J. Med, vol. 91, pp. 411-415, 1998.
C. Monaco et al., “Autoantibodies against oxidized low density lipoproteins in patient with stable angina, unstable angina or peripheral vascular disease”, European Heart Journal, vol. 22, pp. 1572-1577, 2001.
E. Matsuura et al., “Anticardiolipin Antibodies Recognize β2-Glycoprotein I Structure Altered by Interacting with an Oxygen Modified Solid Phase Surface”, J. Exp. Med., vol. 179, pp. 457-462, Feb. 1994.
B. Bouma et al., “Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure”, The EMBO Journal, vol. 18, No. 19, pp. 5166-5174, 1999.
M. Hoshino et al., “Identification of the Phospholipid-binding Site of Human β2-Glycoprotein I Domain V by Heteronuclear Magnetic Resonance”, J. Mol. Biol., vol. 304, pp. 927-939, 1998.
D. Hong et al., “Flexible Loop of β2-Glycoprotein I Domain V Specifically Interacts with Hydrophobic Ligands”, Biochemistry, vol. 40, pp. 8092-8100, 2001.
Y. Hasunuma et al., “Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages”, Clin. Exp. Immunol., vol. 107, pp. 569-573, 1997.
L. Kritharides et al., “A Method for Defining the Stages of Low-Density Lipoprotein Oxidation by the Separation of Cholesterol-and Cholesteryl Ester-Oxidation Products using HPLC”, Analytical Biochemistry, vol. 213, pp. 79-89, 1993.
J. George et al., “Induction of Early Atherosclerosis in LDL-Receptor-Deficient Mice Immunized with β2-Glycoprotein I”, Basic Science Reports, pp. 1108-1114, Sep. 15, 1998.
J. George et al., “Immunolocalization of β2-Glycoprotein I (Apolipoprotein H) to Human Atherosclerotic Plaques” Basic Rapid Communication, pp. 2227-2229, May 4, 1999.
E. Matsuura et al., “Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship”, International Immunology, vol. 12, No. 8, pp. 1183-1192, 2000.
P. Holvoet et al., “Oxidized LDL and Malondialdehyde-Modified LDL in Patients with Acute Coronary Syndromes and Stable Coronary Artery Disease”, American Heart Association, pp. 1487-1494, Oct. 13, 1998.
K. Ichikawa et al., “A Chimeric Antibody with the Human γ1 Constant Region as a Putative Standard for Assays to Detect IgG β2Glycoprotein I-Dependent Anticardiolipin and Anti-β2-Glycoprotein I Antibodies”, Arthritis & Rheumatism, vol. 42, No. 11, pp. 2461-2470, Nov. 1999.
A. Ambrozic et al., “Anti-β2-glycoprotein I antibodies in children with atopic dermatitis”, International Immunology, vol. 14, No. 7, pp. 823-830, 2002.
Q. Liu et al., “ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages”, Journal of Lipid Research, vol. 43, pp. 1486-1494, 2002.
G. M. Iverson et al., “The Orientation of β2GPI on the Plate is Important for the Binding of Anti-β2GPI Autoantibodies by ELISA”, Journal of Autoimmunity, vol. 18, pp. 289-297, 2002.
E. Matsuura et al., “Anti-β2-Glycoprotein I Autoantibodies and Atherosclerosis”, Intern. Rev. Immunol., vol. 21, pp. 51-66, 2002.
S. Yasuda et al., “β2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis”, Atherosclerosis, vol. 152, pp. 337-346, 2000.
J. George et al., “Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)”, Clin. Exp. Immunol., vol. 108, pp. 227-233, 1997.
Koike, “Antiphospholipid antibodies in arterial thrombosis”, Annals of Medicine, vol. 32, No. Supp. 1, 2000, pp. 27-31.
E. Matsuura et al., “Anti-β2-Glycoprotein I Autoantibodies and Atherosclerosis”, International Reviews of Immunology, vol. 21, No. 1, pp. 51-66, Jan.-Feb. 2002.
Q. Liu et al., “ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages”, Journal of Lipid Research, vol. 43, No. 9, pp. 1486-1495, Sep. 2002.
E. Matsuura et al., “Autoantibody-mediated atherosclerosis”, Autoimmunity Reviews, vol. 1, No. 6, pp. 348-353, Aug. 25, 2002.
M. J. Cuadrado et al., “Antiphospholipid, anti-β2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome”, QJM - Monthly Journal of the Association of Physicians, vol. 91, No. 9, pp. 619-626, Sep. 1998.
Cheu Changhwa J
Le Long V.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method of measuring oxidized LDL/β2-glycoprotein I... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of measuring oxidized LDL/β2-glycoprotein I..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of measuring oxidized LDL/β2-glycoprotein I... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036091